Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

Research scientists working in laboratory

Bisphosphonates, a drug class used to prevent the loss of bone density, are the first-line treatment for preventing fracture in osteoporosis patients. Osteoporosis is often associated with patients with chronic kidney disease (CKD), who can suffer from low bone density and increased fracture risk, but there was little information available on the safety of bisphosphonates in patients with CKD.

Moderate to severe (stages 3-5) chronic kidney disease (CKD) affects up to 2.8 million people in the UK and 2.7 million people in Spain.

The Prieto-Alhambra Group for pharmaco- and device epidemiology at NDORMS, in collaboration with SIDIAP, set out to understand the safety profile of bisphosphonates in patients with moderate to severe CKD. Using primary-care electronic records from two patient cohorts in the UK and Catalonia, Spain, they analysed the data from 4,000 bisphosphonate users and more than 15,000 non-users.

Victoria Strauss, lead statistician at NDORMS said: “Our primary outcome was CKD stage worsening, the risk that patients may move to a more severe form of the disease and which could potentially lead to dialysis or transplant. We saw a modest (15%) risk of CKD progression with bisphosphonate use. This adds to the body of work in this area and should act as a guide to clinicians to carefully consider the risk-benefit of prescribing bisphosphonate to moderate to severe CKD patients for the management of osteoporosis.”

The study found no risk differences for acute kidney injury, gastrointestinal bleeding/ulcers, or hypocalcaemia.

The study, published in JMBR (Journal of Molecular Biology Research), was funded by the Health Technology Assessment Programme, and the Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable, and supported by the NIHR Bio-medical Research Centre.

Similar stories

NDORMS researchers awarded funding by The Paget’s Association

Professor Philippa Hulley and Doctor Helen Knowles have been awarded funding by The Paget’s Association for their research on bone cells.

NDORMS researchers awarded NIHR Fellowships

Six researchers from the Botnar Research Centre have been awarded NIHR (National Institute for Health Research) Fellowships.

Oxford-Bristol Myers Squibb Fellowships awarded to NDORMS researchers

Six researchers from the Botnar Research Centre and the Kennedy Institute of Rheumatology at NDORMS have been awarded fellowships as part of the Oxford-Bristol Myers Squibb Fellowship Programme, providing them an opportunity to gain exposure to the field of commercial drug discovery and development.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

NDORMS researchers join new multidisciplinary oncology research project

OPTIMA aims to improve treatment for patients with prostate, breast and lung cancer through artificial intelligence

Professor David Beard awarded BOA Honorary Fellowship

Professor of Musculoskeletal and Surgical Science, David Beard, has been awarded an Honorary Fellowship by the British Orthopaedic Association.